Navigation Links
Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
Date:7/17/2008

Thomas Will Focus on Strategies to Promote Legislative Pathway for

Follow-On Biologics

RICHMOND, Va., July 17 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals for unmet medical needs, today announced that The Honorable Bill Thomas, Former Chairman of the House Ways and Means Committee from 2001 to 2007, has been retained by Insmed as a strategic advisor to assist the Company's efforts to bring follow-on biologics to U.S. customers and consumers.

Bill Thomas played a critical role developing key health legislation during his 28 years of service in the US House of Representatives, culminating in the passage of the Medicare Modernization Act of 2003, which created Medicare Part D prescription drug coverage for seniors.

"During my time in Congress I helped lay the groundwork to allow biologic competition from follow-on biologics. I am excited to partner with Insmed to continue that fight," said Chairman Thomas. "Biotechnology represents the future of modern healthcare in America, but as is the case across all industries in our economy, competition will foster innovation and benefits for consumers," Thomas continued. "Insmed is walking the walk, having already produced data showing bioequivalence between one of their products and a pioneer drug. Given the rising costs of healthcare, Congress needs to pass legislation creating a pathway for follow-on biologics."

The announcement follows Insmed's release of data last week demonstrating bioequivalence between INS-19 and Neupogen(R) (patented in 1996) in Phase I clinical trials. In the coming months, Insmed will seek FDA approval to begin Phase III clinical trials for INS-19 and also initiate Phase I trials for Insmed's second follow-on biologic product, INS-20, a generic form of Neulasta(R) (patented in 1998). The two biologics represented combined 2007 worldwide sales of over $4 billion. Insmed p
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
2. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
3. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
4. Insmed Announces First Quarter 2008 Financial Results
5. Insmed to Present at CBI Follow-On Biologics Conference
6. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
7. Insmed Announces Additional Information in Compliance With NASDAQ Rules
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
10. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
11. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Biotechnology industry pioneer Amgen (NASDAQ: ... BlackLine Systems  and enterprise application software leader ... webinar next week entitled "No Account Left Behind!  ... to Help Keep Its Account Reconciliations in Good Shape ... The webinar, geared at finance, accounting, audit and compliance ...
(Date:6/19/2013)... BioConvergence team members Curtis Strother ... 2013’s BioLogistics Summit in San Francisco earlier this ... Chain IQ and IQPC, addressed the increasingly complex ... part, attributed to current trends of globalization, outsourcing, ... trends is an increase in movement, which is ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased ... measurement of sulfur in ultra-low sulfur diesel (ULSD) using ... EDXRF analyzer . The analysis detailed in Rigaku Application ... This International Standard specifies an energy dispersive X-ray ... content in automotive gasoline. , Regulations around the world ...
(Date:6/19/2013)... 19, 2013 Express Diagnostics Int’l, Inc., ... announced that it has received Class III medical device ... its DrugCheck® NxStep Onsite Drug Screen Cup ... rapid screening device in near-patient settings, such as physicians’ ... received Health Canada Class III approval for 24 different ...
Breaking Biology Technology:Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... Encorium Group, Inc. (Nasdaq: ENCO ), a full service ... for many of the world,s leading pharmaceutical and biotechnology companies, today ... Nasdaq stating that since it had not, as of the date ... June 30, 2009, it was then no longer in compliance with ...
... , MURRIETA, Calif., Aug. 27 Despite ... of its US operations. Copan Diagnostics, Inc. is undertaking a ... and additional medical device manufacturing operations to its facility in ... molding machinery and filling and packing equipment to expand Copan,s ...
... , , , , ... PPHM ) today announced that it will release its financial results for ... 7:00 a.m. EDT and will host a conference call and webcast to ... , Peregrine,s senior management will discuss financial results for ...
Cached Biology Technology:Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing 2Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing 3Copan Announces Multimillion Expansion for US Pipet Manufacturing Operations 2Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results 2
(Date:6/19/2013)... June 19, 2013 MedNet Solutions , ... study management systems, is pleased to announce its participation ... June 23-27 in Boston .  This ... recognized leader in cloud-based eClinical solutions, has exhibited at ... showcasing iMedNet™ EDC , MedNet,s latest, ...
(Date:6/19/2013)... the most perfectly spherical large objects in nature may ... new study. It appears in ACS, journal Langmuir ... Julyan Cartwright, Antonio G. Checa and Marthe Rousseau point ... have perhaps the most perfectly spherical, or ball-like, shape ... without a microscope. Pearls develop as nacre (mother of ...
(Date:6/19/2013)... 2012, the European Medicines Agency (EMA) approved the ... ever gene therapy for clinical use in the ... developed AAV-LPL S447X for the treatment of a ... (LPLD) which affects approximately one or two out ... life-threatening inflammations of the pancreas. Afflicted individuals carry ...
Breaking Biology News(10 mins):MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2No danger of cancer through gene therapy virus 2
... Cones, holes and temporary traffic lights the scourge of ... together to reduce the misery of motorists caused by ... under the tarmac. They,ll reveal how new technology will ... digging. A sector-wide seminar at The University of ...
... New Orleans, LA Research led by David Worthylake, PhD, ... Sciences Center New Orleans, may help lay the groundwork for ... cancer. The research will be published in the May 29, ... During the transition from a localized tumor to metastatic ...
... NOT trying to assert their dominance over their canine ... at the University of Bristol,s Department of Clinical Veterinary ... Applications and Research . The researchers spent six ... rehoming centre, and reanalysing data from studies of feral ...
Cached Biology News:Reducing the roadworks 2Reducing the roadworks 3LSUHSC research describes function of key protein in cancer spread 2Using 'dominance' to explain dog behavior is old hat 2
... BAS-2500 is ideal for ... Biology (1D electrophoresis, 2D ... Macroarrays); Pharmacokinetics & Toxicology ... layer chromatography); Physical and ...
BlotGel application pool -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
Biology Products: